<DOC>
	<DOCNO>NCT02688075</DOCNO>
	<brief_summary>The purpose study evaluate canagliflozin use treatment type 2 diabetes mellitus ( T2DM ) generate evidence effectiveness , safety patient-reported outcome ( PRO ) usual clinical practice Canada .</brief_summary>
	<brief_title>An Observational Study Assess Canagliflozin Treatment Type 2 Diabetes Mellitus Usual Clinical Practice Canada</brief_title>
	<detailed_description>This prospective , non-interventional , nation-wide , multicenter ( one study site ) study evaluate treatment T2DM canagliflozin usual clinical practice Canada . Approximately 535 participant enrol study . The plan study duration participant 12 month [ plus minus ( +/- ) 4 week ] , include 4 study visit accordance usual clinical practice : enrollment visit 3 , 6 12 month ( +/- 4 week ) . Participants primarily observe effectiveness , safety PRO observational period 12 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Participant must diagnosis type 2 diabetes mellitus ( T2DM ) glycosylated hemoglobin ( HbA1c ) great equal ( &gt; = ) 7 percent ( % ) baseline Participant must stable antihyperglycemic treatment regimen least 30 day prior canagliflozin initiation Participant must estimate glomerular filtration rate ( eGFR ) &gt; =60 milliliter ( mL ) /minute ( min ) /1.73 meter^2 ( m^2 ) Must sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor naive participant initiate canagliflozin treatment prior study enrollment Participant must provide write consent data collection signing ICF indicate understand procedure data collection willing participate study Participants history SGLT2 inhibitor use ( canagliflozin , empagliflozin , dapagliflozin SGLT2 inhibitor ) Participants history diabetic ketoacidosis ( DKA ) , autoimmune diabetes ( example , type 1 diabetes mellitus [ T1DM ] latent autoimmune diabetes adult [ LADA ] ) , pancreas betacell transplantation , diabetes secondary pancreatitis pancreatectomy Participants receive investigational drug ( include vaccine ) within 3 month initiation canagliflozin Participant currently enrol plan enroll investigational study Participant pregnant breastfeeding planning become pregnant breast feed study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Observational Study</keyword>
</DOC>